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ABSTRACT 
 
Over the recent decades the interest in intranasal delivery as a non-invasive route for drugs is increased. 
Since the nasal mucosa offers numerous benefits as a target tissue for drug delivery, a wide variety of 
therapeutic compounds may be administered intranasally for topic, systemic and central nervous system 
action. We have, herein, outlined the relevant aspects of nasal anatomy, physiology and histology, and the 
biological, physicochemical and pharmaceutical factors that must be considered during the process of 
discovery and development of nasal drugs as well as in their incorporation into appropriate nasal 
pharmaceutical formulations. 
_______________________________________________________________________________________ 
 
1. INTRODUCTION 
 
Oral drug delivery is the most desirable route for 
drug administration whenever systemic effects are 
intended. Therefore, it is not surprising that the 
prediction of human oral bioavailability of new 
drug candidates is currently targeted from the 
earliest stages of drug discovery and development 
programmes (1, 2). However, although the oral 
route remains the most popular for systemic drug 
administration, low oral bioavailability of some 
compounds has prompted the search of more 
effective routes for their systemic delivery (3). 
Intranasal drug delivery is now recognized to 
be a useful and reliable alternative to oral and 
parenteral routes. Undoubtedly, the intranasal 
administration of medicines for the symptomatic 
relief and prevention or treatment of topical nasal 
conditions has been widely used for a long period 
of time. However, recently, the nasal mucosa has 
seriously emerged as a therapeutically viable 
route for the systemic drug delivery. In general, 
among the primary targets for intranasal 
administration are pharmacologically active 
compounds with poor stability in gastrointestinal 
fluids, poor intestinal absorption and/or extensive 
hepatic first-pass elimination, such as peptides, 
proteins and polar drugs (4). The nasal delivery 
seems to be a favourable way to circumvent the 
obstacles for blood-brain barrier (BBB) allowing 
the direct drug delivery in the biophase of central 
nervous system (CNS)-active compounds. It has 
also been considered to the administration of 
vaccines (5-8). 
The widespread interest in intranasal route for 
therapeutic purposes other than the topically nasal 
drug delivery arises from the particular 
anatomical, physiological and histological 
characteristics of the nasal cavity, which provides 
potential for rapid systemic drug absorption and 
quick onset of action. In addition, intranasal 
absorption avoids the gastrointestinal and hepatic 
presystemic metabolism, enhancing drug 
bioavailability in comparison with that obtained 
after gastrointestinal absorption (9, 10). On the 
other hand, intranasal administration also offers 
several practical advantages either from the 
viewpoint of patients (non-invasiveness, 
essentially painless, ease drug delivery and 
favourable tolerability profile) or pharmaceutical 
industry (unnecessary sterilization of nasal 
preparations) (11, 12). Hence, bearing in mind the 
intrinsic value of intranasal route to overcome 
patient compliance concerns together with its 
pharmacokinetic advantages, it appears to be an 
appropriate route for the treatment of not only 
acute or chronic nasal diseases, but also for a 
range of acute or chronic conditions requiring 
considerable systemic drug exposure (4, 12). 
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Despite its advantages, the nasal drug 
administration presents some limitations that must 
be considered during the discovery of new 
chemical entities intended for nasal therapy as 
well as during the development of nasal 
formulations. First of all, in addition to 
physicochemical properties of drugs and 
characteristics of their final formulations, a 
variety of physiological and pathological 
conditions related to nasal mucosa may also 
compromise the extent of nasal drug absorption 
and therapy efficacy (7, 11, 13). Furthermore, the 
low volume of nasal cavity restricts the amount of 
drug formulation administered to about 100-150 
μL (13). Consequently, particular problems may 
appear if nasal delivery of high doses of poorly 
water-soluble drugs is necessary. Nevertheless, 
these drawbacks are often overcome making use 
of medicinal chemistry and/or pharmaceutical 
technology-strategies involving for instance the 
synthesis of prodrugs and/or the use of enhancers 
or bioadhesive polymers to increase drug 
permeability and residence time in nasal cavity. 
Enzymatic inhibitors may also be employed to 
protect drugs against enzymatic degradation in the 
nasal mucosa. However, care should be taken in 
the use of such compounds due to their possible 
risks to develop nasal irritation and/or systemic 
toxic effects (14). 
In the last few years a number of excellent 
reviews have been published examining in detail 
some particular aspects concerning to potential 
therapeutic applications of intranasal route of 
drug delivery (15-23). However, general reviews 
gathering together information about special 
characteristics of nasal mucosa, desirable 
physicochemical properties of drugs for nasal 
administration and successful technology-
strategies to develop pharmaceutical formulations 
for topically or systemically intranasal drug 
delivery are lacking. Accordingly, the present 
review outlines anatomical, physiological and 
histological features of nasal cavity and the major 
factors affecting nasal drug delivery, highlighting 
simultaneously the properties of drugs and 
formulation characteristics that determine 
decisively the pharmacokinetics of nasal 
preparations. Additionally, the rationale for the 
extensive research of nasal medicines with current 
and future drug therapies, as well as their 
therapeutic benefit, will be also considered 
whenever appropriated. 
2. NASAL CAVITY: ANATOMY, 
PHYSIOLOGY AND HISTOLOGY 
 
In humans and other animal species the major 
functions of the nasal cavity are breathing and 
olfaction (24). However, it also affords an 
important protective activity once it filters, heat 
and humidify the inhaled air before reaching the 
lowest airways. Nasal cavity is lined with mucus 
layer and hairs which are involved in those 
functions, trapping inhaled particles and 
pathogens. Moreover, resonance of produced 
sounds, mucociliary clearance MMC, 
immunological activities and metabolism of 
endogenous substances are also essential 
functions of nasal structures (25-28). 
Anatomic and histological characteristics of 
the different areas of nasal cavity are such that 
allow these functions to be performed optimally. 
Thus, anatomically, human nasal cavity fills the 
space between the base of the skull and the roof 
of the mouth; above, it is supported by the 
ethmoid bones and, laterally, by the ethmoid, 
maxillary and inferior conchae bones (25). The 
human nasal cavity has a total volume of 15-20 
mL and a total surface area of approximately 150 
cm2 (10, 29). It is divided by middle (or nasal) 
septum into two symmetrical halves, each one 
opening at the face through nostrils and extending 
posterior to the nasopharynx. Both symmetrical 
halves consist of four areas (nasal vestibule, 
atrium, respiratory region and olfactory region) 
that are distinguished according to their anatomic 
and histological characteristics (Figure 1; Table 
1). 
 
2.1. Nasal vestibule 
 
Nasal vestibule is the most anterior part of the 
nasal cavity, just inside the nostrils, and presents 
an area about 0.6 cm2 (4). Here, there are nasal 
hairs, also called vibrissae, which filter the 
inhaled particles. Histologically, this nasal portion 
is covered by a stratified squamous and 
keratinized epithelium with sebaceous glands (4, 
27, 28). These nasal vestibular characteristics are 
desirable to afford high resistance against toxic 
environmental substances but, at the same time, 
the absorption of substances including drugs 
becomes very difficult in this region (30). 
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Figure 1. Anatomy and histology of human nasal cavity. 
 
Table 1. Human nasal epithelium characteristics (4, 10, 27, 35). 
 
Nasal 
Sections 
Epithelial Characteristics 
Cells / Functions 
Surface 
Area 
Vascularization Permeability 
Vestibule  Stratified squamous and keratinized 
epithelial cells with nasal hairs / Support 
and protection 
≈ 0.6 cm2 Low Poor 
  
Atrium  Stratified squamous cells / Support 
 Pseudostratified cells / Support 
NF Low Reduced 
  
Respiratory 
region 
 Columnar non ciliated cells / Support 
 Columnar ciliated cells / Support and 
muciliary clearance 
 Globet cells / Mucus secretion 
 Basal cells / Progenitors of other cell 
types 
≈ 130 cm2 Very high Good 
  
Olfactory 
region 
 Sustentacular cells / Support and synthetic 
 Olfactory receptor cells / Olfaction 
perception 
 Basal cells / Progenitors of other cell 
types 
≈ 15 cm2 High Direct access 
to CNS 
NF, not found.  
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2.2. Atrium 
 
Atrium is the intermediate area between nasal 
vestibule and respiratory region. Its anterior 
section is constituted by a stratified squamous 
epithelium and the posterior area by 
pseudostratified columnar cells presenting 
microvilli (27, 28). 
 
2.3. Respiratory region 
 
The nasal respiratory region, also called conchae, 
is the largest part of the nasal cavity and it is 
divided in superior, middle and inferior turbinates 
which are projected from the lateral wall. These 
specialized structures are responsible for 
humidification and temperature regulation of 
inhaled air. Between them there are spaces, called 
meatus, which are passageways where airflow is 
created to assure a close contact of the inhaled air 
with the respiratory mucosal surface. The inferior 
and middle meatus receive nasolacrimal ducts and 
paranasal sinuses which are air-filled pockets 
located inside the bones of the face and around 
the nasal cavity (31). 
The nasal respiratory mucosa, considered the 
most important section for delivering drugs 
systemically, is constituted by the epithelium, 
basement membrane and lamina propria. The 
nasal respiratory epithelium consists of 
pseudostratified columnar epithelial cells, globet 
cells, basal cells and mucous and serous glands 
(25, 27, 28). Many of the epithelial cells are 
covered on their apical surface with microvilli and 
the major part of them also has fine projections, 
called cilia (28). Actually, microvilli are 
important to enhance the respiratory surface area, 
while cilia are essential to transport the mucus 
toward the nasopharynx. Under physiological 
conditions, nasal epithelium is covered with a thin 
mucus layer produced by secretory glands and 
globet cells. These ones secrete granules filled 
with mucin, a glycoprotein that determines the 
viscosity of the mucus. The nasal mucus layer is 
only 5 μm thick and it is organized in two distinct 
layers: an external, viscous and dense, and an 
internal, fluid and serous. Overall, nasal mucus 
layer consists of 95% of water, 2.5-3% of mucin, 
and 2% of electrolytes, proteins, lipids, enzymes, 
antibodies, sloughed epithelial cells and bacterial 
products (32-34). Nasal mucus is indispensable 
for several physiological functions, such as 
humidification and warming of the inhaled air, 
and also offers physical and enzymatic protection 
of the nasal epithelium against several foreign 
compounds, including drugs. The protective 
action results of the adhesive characteristics of 
mucus to attract inhaled particles or pathogens, 
which are removed towards the nasopharynx by 
nasal MCC (35). The presence of mucin in the 
nasal mucus layer is crucial because it may trap 
large molecular weight drugs, such as peptides 
and proteins (13). The basal cells that exist in the 
epithelium are progenitors of other cell-types and 
lye on a thickened layer of collagen called 
basement membrane. Beneath of it, there is the 
lamina propria which is richly supplied with 
blood vessels, including many very permeable 
fenestrated capillaries, nerves, glands and immune 
cells. The last ones produce immunoglobulin A 
antibodies that confer immunological protection 
against bacteria and virus (36). 
 
2.4. Olfactory region 
 
The olfactory region is located in the roof of the 
nasal cavity and extends a short way down the 
septum and lateral wall (27). Its neuroepithelium 
is the only part of the CNS that is directly 
exposed to the external environment (37). 
Similarly to the respiratory epithelium, the 
olfactory one is also pseudostratified but contains 
specialized olfactory receptor cells important for 
smell perception (27, 37). In this area there are 
also small serous glands (glands of Bowman) 
producers of secretions acting as a solvent for 
odorous substances (27). 
 
3. INTRANASAL DRUG DELIVERY  
 
Over the last years, due to the understanding of 
the positive attributes and appropriate 
characteristics of the nasal cavity, intranasal route 
has been increasingly considered for drug 
delivery when developing new chemical entities 
or improving the therapeutic profile of existing 
drugs. However, to assess the therapeutic viability 
of intranasal drug delivery several approaches 
should be considered, attending, specifically, to 
the nature of pathologic condition (acute or 
chronic) and intended effects of drug treatment 
(local, systemic or at CNS). Indeed, for acute 
disease conditions, the advantages afforded by 
intranasal drug delivery in terms of patient 
comfort and compliance may not be much 
relevant when compared with drug delivery by 
parenteral route. In contrast, this is particularly 
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important to treat or control chronic medical 
conditions (38). 
 
3.1 Local delivery 
 
Intranasal administration of medicines is the 
natural choice for the treatment of topical nasal 
disorders. Among the most common examples are 
antihistamines and corticosteroids for 
rhinosinusitis, and nasal decongestants for cold 
symptoms (Table 2). In these cases, intranasal 
route is the primary option for drug delivery 
because it allows a rapid symptom relief with a 
more favourable adverse-event profile than oral or 
parenteral routes. In fact, relatively low doses are 
effective when administered topically (40), 
minimizing simultaneously the potential of 
systemic toxic effects. Recently, for instance, 
topical antibiotherapy has been considered in 
chronic rhinosinusitis in an attempt to eradicate 
biofilm bacteria, often resistant to systemic 
treatment, and still avoiding systemic toxicity (41-
46). 
 
3.2. Systemic delivery 
 
The intranasal administration is an effective way 
to systemically delivery of drugs as an alternative 
to oral and intravascular routes. Actually, it seems 
to present fast and extended drug absorption (47), 
and it has been supported by many studies 
planned to compare intranasal drug delivery 
against oral and parenteral administration (Figure 
2) (9, 49, 50). Consequently, the number of drugs 
administered as nasal formulations intended to 
achieve systemic effects has widely increased. 
Some prominent examples include analgesics 
(morphine) (4, 7, 51), cardiovascular drugs as 
propranolol (52) and carvedilol (53), hormones 
such as levonorgestrel (48), progesterone (54) and 
insulin (49, 55-57), anti-inflammatory agents as 
indomethacin (58, 59) and ketorolac (60, 61), and 
antiviral drugs (acyclovir) (62-65). Actually, there 
are some examples already available in the market 
(Table 2). These include, for instance, 
zolmitriptan and sumatriptan for the treatment of 
migraine and cluster headaches. 
 
3.3 Nasal vaccines 
 
Nasal mucosa is the first site of contact with 
inhaled antigens (4, 13) and, therefore, its use for 
vaccination, especially against respiratory 
infections, has been extensively evaluated. In fact, 
nasal vaccination is a promising alternative to the 
classic parenteral route, because it is able to 
enhance the systemic levels of specific 
immunoglobulin G and nasal secretory 
immunoglobulin A (58, 66-68). In upper airways, 
the systemic and local immunological responses 
are mainly mediated by the nasal associated 
lymphoid tissue situated underneath the nasal 
epithelium. The nasal associated lymphoid tissue 
is composed of agglomerates of dendritic cells, T-
cells and B-cells which are involved in the 
initiation and execution of immune responses 
(68). Examples of the human efficacy of 
intranasal vaccines include those against influenza 
A and B virus, proteosoma-influenza (69), 
adenovirus-vectored influenza (70), group B 
meningococcal native (71), attenuated respiratory 
syncytial virus (72) and parainfluenza 3 virus (72, 
73) (Table 2). However, human nasal vaccination 
is not restricted to the upper airways affections. 
After nasal immunization secretory 
immunoglobulin A can also be detected in other 
mucosal secretions, which may be important 
against virus transmitted through other mucosal 
sites, such as human immunodeficiency virus (74) 
and hepatitis B virus (75). 
IN Oral
0
400
800
1200
1600 Cmax (ng/mL) AUC0-12 (ng.h/mL)
416.8
1294.9
334.9
1303.1
 
Figure 2. Plasma pharmacokinetic parameters obtained after intranasal (IN) and oral administration of 
levonorgestrel (500µg) in rats (48). 
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Table 2. Examples of nasal formulations commercially available after prescription (4, 6, 13, 39). 
Drug Brand Main Excipients Supplier Main Indications 
Local Delivery 
Azelastine  Astelin Benzalkonium chloride, 
edetate disodium, 
hypromellose
Meda Pharmaceuticals 
Management/treat
ment of symptoms 
of seasonal and 
perennial rhino-
sinusitis 
Beclometasone  Beconase Microcrystalline cellulose, 
carboxymethyl cellulose 
sodium, 
benzalkonium chloride 
GlaxoSmithKline 
Budesonide Rhinocort Microcrystalline cellulose, 
carboxymethyl cellulose 
sodium, dextrose anhydrous 
AstraZeneca  
Levocabastine  Livostin Benzalkonium chloride, 
edetate disodium, disodium 
phosphate 
Jansen-Cilag 
Mometasone  Nasonex Microcrystalline cellulose, 
carboxymethylcellulose 
sodium, benzalkonium 
chloride 
Schering-Plough  
Olapatadine  Patanase Benzalkonium chloride, 
dibasic sodium phosphate, 
edetate disodium  
Alcon Laboratories 
Sodium 
cromoglicate 
Nasalcrom Benzalkonium chloride, 
edetate disodium 
Sanofi-Aventis 
Triamcinolone 
acetonide 
Nasacort Microcrystalline cellulose, 
carboxymethylcellulose 
sodium, polysorbate 80 
Sanofi Aventis 
 
Mupirocin 
 
Bactroban 
 
Paraffin and a mixture of 
glycerin esters (Softisan 649) 
 
GlaxoSmithKline 
 
Eradication of nasal 
staphylococci 
Systemic Delivery 
Estradiol Aerodiol Methylbetadex, sodium chloride Servier laboratories 
Hormone 
replacement 
therapy 
Nicotine Nicotrol NS 
Disodium phosphate, 
sodium dihydrogen 
phosphate, citric acid 
Pfizer Smoking cessation 
Cyanocobalamin Nascobal Sodium citrate, citric acid, benzalkonium chloride 
Strativa 
pharmaceuticals 
Vitamin B12 
deficiency 
Desmopressin Desmospray 
Sodium chloride, citric 
acid, benzalkonium 
chloride 
Ferring 
Pharmaceuticals 
Control of 
dehydration in 
diabetes insipidus 
Oxytocin Syntocinon Citric acid, chlorobutanol, sodium chloride Novartis  
Labour induction; 
lactation 
stimulation 
Salmon 
calcitonin Miacalcin 
Sodium chloride, 
benzalkonium chloride, 
hydrochloric acid 
Novartis  
Treatment of post-
menopausal 
osteoporosis 
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3.4. CNS delivery through nasal route 
 
The brain is a delicate organ with many vital 
functions and it is isolated and protected from the 
outside environment by several intriguing 
mechanisms. Unfortunately, those are the same 
mechanisms that prevent the CNS delivery of 
therapeutic agents. The tight junctions of the BBB 
surrounding the brain is one of such mechanisms 
(8), resulting in a greater transendothelial electric 
resistance (1500-2000 Ω.cm2) compared to that of 
other tissues like skin, bladder, colon, lungs (3-33 
Ω.cm2) (76). This histological organization 
impairs, therefore, the systemically delivery of 
CNS-active drugs. Even though, if drugs or other 
xenobiotics pass through the BBB, a second line 
of defence mechanisms, including multidrug 
efflux protein transporters, may reduce the brain 
exposure. It is estimated that almost half of drug 
candidates are substrates to P-glycoprotein (P-gp) 
efflux pump, presenting reduced potential for 
systemically CNS penetration (77, 78). 
The obstacle imposed by those brain 
protective mechanisms has increased the interest 
in developing strategies to overcome them when 
brain drug exposure is required. In this context, 
over the last few years, intranasal route has 
emerged as a promising approach for brain 
delivery of drugs. The delivery from the nose to 
the CNS may occur via olfactory neuroepithelium 
and may involve paracellular, transcellular and/or 
neuronal transport (4, 75, 79). Although the 
olfactory pathway presents potential to bypass 
BBB, P-gp appears to be also functional on this 
area (8, 76, 80-82). Graff et al. (81) confirmed 
that P-gp is present in both the olfactory 
epithelium and endothelial cells that surround the 
olfactory bulb. Moreover, the transport via 
trigeminal nerve system from the nasal cavity to 
CNS has also been described (83). 
Drug delivery into CNS through intranasal 
route has been reported (84-87) either in humans 
or animal models of Alzheimer’s disease (88, 89), 
brain tumours (90, 91), epilepsy (92), pain (82) 
and sleep disorders (93). However, it should be 
noted that in other cases evidence is lacking 
supporting the greater brain exposure via 
intranasal delivery despite the needless of passage 
BBB and the absence of gastrointestinal and 
hepatic presystemic elimination (94-97). 
 
 
Table 2 continued..... 
Buserelin Suprefact 
Sodium hydroxide, sodium 
chloride, sodium 
dihydrogen phosphate
Sanofi-Aventis Treatment of prostate cancer 
Nafarelin  Synarel Benzalkonium chloride, glacial acetic acid Roche Laboratories 
Management of 
endometriosis 
Zolmitriptan Zomig 
Nasal 
Citric acid, disodium 
phosphate dodecahydrate  
 
AstraZeneca  
Treatment of 
migraine and 
cluster headaches Sumatriptan Imigran Potassium dihydrogen phosphate, dibasic sodium 
phosphate anhydrous 
GlaxoSmithKline 
Fentanyl Instany Sodium dihydrogen 
phosphate dehydrate, 
disodium phosphate 
dehydrate 
Nycomed Pharma 
Pain management 
Butorphanol Stadol NS Sodium chloride, citric 
acid, benzethonium 
chloride  
Bristol-Myers Squibb 
Live attenuated 
influenza 
vaccine 
FluMist 
Monosodium glutamate, 
hydrolyzed porcine gelatin, 
arginine, dibasic potassium 
phosphate, monosodium 
phosphate, gentamicin 
sulfate 
MedImmune, Inc. Flu prevention 
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4. FACTORS INFLUENCING NASAL DRUG 
ABSORPTION 
 
When a drug is nasally administered to induce 
systemic effects or to act into CNS it needs to 
pass through the mucus layer and epithelial 
membrane before reaching the blood stream or 
pass directly to the CNS. The passage across the 
epithelium may occur by transcellular or 
paracellular mechanisms. The first one includes 
passive diffusion through the interior of the cell 
and it is especially involved in the transport of 
lipophilic drugs (11). However, it seems that 
compounds with a molecular weight higher than 1 
kDa, such as peptides and proteins, are 
transcellularly transported by endocytic processes 
(13, 35). Furthermore, transcellular transport can 
be mediated by carriers that exist in the nasal 
mucosa, including organic cation transporters and 
amino acids transporters (76, 80-82). In contrast, 
paracellular route is involved in the transport of 
small polar drugs and it takes place between 
adjacent epithelial cells through hydrophilic 
porous and tight junctions. Tight junctions are 
dynamic structures localized between the cells, 
which open and close accordingly to 
(in)activation of signalling mechanisms. 
Nevertheless, it is well known that their size is 
comprised between 3.9-8.4 Å (98), avoiding the 
passage of bigger molecules, being this process of 
transport highly dependent of drug molecular 
weight (99). 
 Taking into account previous 
considerations, it is evident that the molecular 
weight and lipophilicity of drugs may have a great 
impact in the rate and extent of its nasal 
absorption. However, other physicochemical drug 
properties must be considered as well as the 
characteristics of drug formulation (7, 11, 13). In 
this section all these factors will be discussed 
after a review of the influence of nasal 
physiological factors on nasal drug absorption.  
  
4.1. Nasal physiological factors 
 
4.1.1. Blood flow 
 
Nasal mucosa is richly supplied with blood and 
presents a large surface area making it an optimal 
local for drug absorption. The blood flow rate 
influences significantly the systemic nasal 
absorption of drugs, so that as it enhances more 
drug passes through the membrane, reaching the 
general circulation. Indeed, bearing in mind that 
most of drug absorption takes place by diffusion, 
the blood flow is essential to maintain the 
gradient of concentration from the site of 
absorption to blood. Hence, it is well known that 
vasodilatation and vasoconstriction may 
determine the blood flow and, consequently, the 
rate and extent of drug to be absorbed. Several 
studies were made to evaluate this influence. For 
example, Huang et al. (100) showed that 
phenylephrine, a vasoconstrictor agent, inhibited 
the absorption of acetylsalicylic acid in nasal 
cavity. More recently, Kao et al. (101) stated that 
nasal absorption of dopamine was relatively slow 
and incomplete probably due to its own 
vasoconstrictor effect. Based on these 
observations, it was concluded that 
vasoconstriction decrease nasal drug absorption 
by diminishing the blood flow. 
 
4.1.2. Mucociliary clearance 
 
MMC also referred to as mucociliary apparatus or 
mucociliar clearance (MCC) is the self-clearing 
mechanism of the bronchi. Nasal mucus layer 
plays an important role in the defence of 
respiratory tract because it prevents the lungs 
from foreign substances, pathogens and particles 
carried by inhaled air. These agents adhere to the 
mucus layer and, all together, they are transported 
to the nasopharynx and, eventually, to the 
gastrointestinal tract. This elimination is 
designated MCC and it influences also 
significantly the nasal drug absorption. The MCC 
system has been described as a ‘‘conveyer belt’’ 
wherein cilia provide the driving force whereas 
mucus acts as a sticky fluid that collects and 
disposes foreign particles (28). The efficiency of 
MCC thereby depends on the length, density and 
beat frequency of cilia as so as the amount and 
viscoelastic properties of mucus. Briefly, all 
factors that increase mucus production, decrease 
mucus viscosity or increase ciliary beat frequency 
may increase the MCC. 
In physiological conditions, mucus is 
transported at a rate of 5 mm/min and its transit 
time in human nasal cavity is reported to be 15-20 
min (4, 35). Values out of these references are 
abnormal and suggestive of impaired MCC (28). 
Thus, if MCC decreases, residence time of the 
drug product in nasal mucosa increase and, 
therefore, enhances its permeation. The opposite 
effect is observed when MCC increases. In the 
last case, a premature discharge of nasally 
administered drugs from nasal cavity toward the 
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nasopharynx occurs, decreasing the amount of 
drug absorbed. The clearance of a drug product 
from the nasal cavity is also influenced by the site 
of deposition. A drug deposited in a posterior area 
of the nose is cleared more rapidly from the nasal 
cavity than a drug deposited anteriorly. This is 
because MCC is slower in the anterior part of the 
nose than in the more ciliated posterior part (28, 
102). On the other hand, the site of drug 
deposition in the nose is highly dependent on the 
dosage form. Nasal sprays deposit drugs more 
anteriorly than nasal drops, resulting in a slower 
clearance for drugs administered from spray 
formulations (4). 
Polar drugs are the most affected by MCC, 
since they are highly soluble in mucus and their 
passage across the membrane is very slow. Thus, 
all factors that influence the efficacy and pace of 
MCC may modify the drug absorption profile. For 
instance, environmental factors have a relevant 
influence in MCC. Temperature and sulphur 
dioxide seem to cause a significant reduction in 
MCC, but this the mechanism is not well known. 
Cigarette smoking also decreases MCC as it 
enhances the viscosity of the mucus and/or 
diminishes the number of cilia. In addition, 
several pathological conditions exist in which 
MCC does not work properly (28, 103, 104), as 
shown in Table 3. Furthermore some components 
of drug formulations may also alter the MCC 
system, such as preservatives and nasal absorption 
enhancers (28). Finally, it is interesting to stand 
out the inter-individual variability observed in 
MCC and the influence of the menstrual cycle and 
circadian rhythm. Actually, during the 
periovulatory period MCC is increased and it is 
reduced at night. 
4.1.3. Enzymatic degradation 
 
Drugs nasally administered circumvent 
gastrointestinal and hepatic first-pass effect. 
However, they may be significantly metabolized 
in lumen of nasal cavity or during the passage 
across the nasal epithelial barrier due to the 
presence of a broad range of metabolic enzymes 
in nasal tissues. Carboxyl esterases, aldehyde 
dehydrogenases, epoxide hydrolases and 
gluthatione S-transferases have been found in 
nasal epithelial cells and are responsible for the 
degradation of drugs in nasal mucosa (105-107). 
Cytochrome P450 isoenzymes are also present 
here and they have been reported as metabolizers 
of drugs such as cocaine, nicotine, alcohols, 
progesterone and decongestants (108, 109). 
Similarly, proteolytic enzymes (aminopeptidases 
and proteases) were found and they are believed 
to be the major barrier against the absorption of 
peptide drugs, such as calcitonin, insulin and 
desmopressin (110, 111). Thus, xenobiotic-
metabolizing enzymes existent in the nasal 
mucosa may affect the pharmacokinetic and 
pharmacodynamic profile of nasally applied 
drugs. In this context, although the nasal first-pass 
metabolism is usually weaker than hepatic and 
intestinal ones it cannot be ignored. 
 
4.1.4. Transporters and efflux systems 
 
The study of transporter systems present in the 
nasal tissue and their effects on the absorption of 
drugs into systemic circulation and CNS is a 
research area in development.  
 
 
 
Table 3. Pathological conditions and their impact in nasal mucociliary clearance (28, 103). 
Pathological conditions Mucociliary clearance 
Primary ciliary dyskinesia  Impaired: absence or dyskinetic beating cilia 
Asthma  Increased: inflammatory process and irritation 
 Decreased: epithelial damage 
Cystic fibrosis  Impaired: dehydratation of mucus 
Viral and bacterial infections  Compromised: loss of cilia and change of mucus properties 
  
Diabetes mellitus  Impaired: dehydratation and microvascular damage 
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Figure 3. P-glycoprotein, an ATP-dependent efflux pump, preventing the influx of a drug (D) from nasal 
membrane to CNS. 
 
 
At the moment, multidrug resistance transporters 
has already been identified in human nasal 
respiratory and olfactory mucosa, which may be 
involved in the transport of a wide variety of 
hydrophobic and amphiphilic drugs (13). P-gp is 
an efflux transporter that exists in the apical area 
of ciliated epithelial cells and in the submucosal 
vessels of the human olfactory region (81). 
Several studies (80-82, 112) demonstrated that P-
gp has an important role in preventing actively the 
influx of drugs from nasal membrane (Figure 3). 
 
4.2. Physicochemical properties of drugs 
 
The influence of physicochemical characteristics 
of drug molecules on the rate and extent of 
gastrointestinal absorption is well understood. 
Therefore, in silico models have been developed 
to prioritize numerous drug candidates at the early 
phases of drug discovery. In same way, but with 
some differences, the physicochemical properties 
of drugs (molecular weight, lipophilicity, pKa, 
stability and solubility) can influence nasal 
absorption. 
 
4.2.1. Molecular weight, lipophilicity and pKa 
 
Lipophilic drugs such as propranolol, 
progesterone and fentanyl are, in general, well 
absorbed from the nasal cavity, presenting 
pharmacokinetic profiles similar to those obtained 
after intravenous administration (Figure 4) and a 
nasal bioavailability near to 100%. Indeed, they 
are quickly and efficiently absorbed across the 
nasal membrane through transcellular 
mechanisms. However, it is important to state that 
this is true for lipophilic compounds presenting a 
molecular weight lower than 1 kDa. The 
extension of nasal absorption of lipophilic drugs 
bigger than 1 kDa is significantly reduced (99). 
On the other hand, the rate and degree of nasal 
absorption of polar drugs is low and highly 
dependent of the molecular weight. Several 
studies (99, 114-116) demonstrated that the 
permeation of polar drugs with a molecular 
weight of less than 300 Da is not considerably 
influenced by their physicochemical properties. 
By contrast, the rate of permeation is highly 
sensitive to molecular size if it is higher than 300 
Da; an inverse relationship exists between rate of 
permeation and molecular weight (114, 115). For 
some small polar molecules only a 10% 
bioavailability is suggested. The value goes down 
to 1% for large molecules such as proteins (117). 
The nasal membrane is predominantly lipophilic, 
hence, drug absorption is expected to diminish 
with a decrease in lipophilicity (114, 118). Thus, 
it is evident that polar drugs are not easily 
transported across nasal membrane thereby 
enhancing MCC. However, if lipophilicity is too 
high, the drug does not dissolve easily in the 
aqueous environment of nasal cavity, hence, with 
Intracellular 
Extracellular 
D 
ATP ADP + Pi 
D
P-glycoprotein 
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accelerated MCC the contact time with nasal 
membrane diminishes resulting in a reduced 
permeation through the wall (119). In general, the 
passage across biomembranes is affected not only 
by lipophilicity/hydrophilicity, but also by the 
amount of drug existing as uncharged species. 
This depends on the drug pKa and the pH of the 
absorption site (5.0-6.5 in human nasal mucosa) 
(26, 35, 120). According to pH partition theory, 
the non-ionized fraction of a drug is more 
permeable than that ionized. For the nasal 
mucosa, a range of studies evaluating the effect of 
lipophilicity and pH on the absorption of small 
drugs were performed (62, 118, 121-123). All of 
them demonstrated that nasal absorption of weak 
electrolytes depends on their ionization degree 
and the largest absorption occurs for the non-
ionized species. In this state, they present a higher 
apparent partition coefficient and, thus, they are 
more lipophilic. However, drugs such as 
acetylsalicylic acid (121) and benzoic acid (122) 
showed some permeability across the membrane 
even in environments that they are expected to 
exist as the ionized species. Based on these 
observations, it was concluded that, for polar 
drugs, partition coefficient is the major factor 
influencing the permeability through nasal 
mucosa. 
 
4.2.2. Stability 
 
During the development of new drug formulations 
biological, chemical and physical drug stability 
studies must be a matter of the major importance 
in all process. As discussed before, the 
environment of nasal cavity has the ability to 
metabolize drugs by defensive enzymatic 
mechanisms, which may reduce the biological 
stability of nasally administered drugs (105-107). 
To overcome this difficulty a variety of strategies 
may be followed, mainly through the use of 
prodrugs (11, 13, 63, 100) and enzymatic 
inhibitors (124-126), as it will be discussed later. 
On the other hand, many drugs may be 
physicochemically instable due to hydrolysis, 
oxidation, isomerisation, photochemical 
decomposition or polymerization reactions (13). 
The same holds true during the intranasal drug 
delivery (6). 
 
4.2.3. Solubility  
 
Drug dissolution is a pre-requisite for any drug 
absorption, since only the molecularly disperse 
form of a drug at the absorption site may cross the 
biomembranes. Hence, before nasal absorption 
the drug must to be dissolved in the watery fluids 
of the nasal cavity. Thus, of the utmost 
importance is the appropriated aqueous drug 
solubility to allow enough contact with the nasal 
mucosa and posterior absorption (123). However, 
the absorption profile is influenced not only by 
drug solubility but also by the nature of 
pharmaceutical preparations, which have to 
guarantee the delivery of drug at therapeutically 
relevant doses. Due to the small size of nasal 
cavity, the allowable volume of drug solution is 
low for intranasal drug administration (13).  
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Figure 4. Plasma pharmacokinetic parameters obtained after intranasal (IN) and intravenous (IV) 
administration of fentanyl (75µg) in man (113). 
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Thereby, drugs poorly soluble in water and/or 
requiring high doses may constitute a problem. 
This can be overtaken enhancing the drug 
aqueous solubility (6, 11, 13, 101, 127). 
 
4.3. Effect of drug formulation 
 
4.3.1. Viscosity 
 
As formulation viscosity increases, the contact 
time between drug and nasal mucosa enhances 
and, thereby, the potential of drug absorption 
increases. At the same time, high viscosity of 
formulations interferes with normal ciliary 
beating and/or MCC and, thus, increases the 
permeability of drugs. This has been observed 
during nasal delivery of insulin (49), acyclovir 
(65) and metoprolol (52). However, sometimes, 
enhancing formulation viscosity does not enhance 
the drug absorption. For example, Zaki et al. 
(123) performed a study to evaluate the influence 
of formulation viscosity on the retention time of 
metoclopramide hydrochloride in nasal cavity and 
on its absorption. Interestingly, they observed that 
although the residence time enhanced as viscosity 
increased the drug absorption diminished. This 
observation has been attributed to a decrease in 
the drug diffusion from the formulation. On the 
other hand, it has also been reported that the 
viscosity of the solution may provide a larger 
therapeutic period of nasal formulations (123). 
 
4.3.2. pH 
 
The extent of nasal absorption depends on the 
pKa of drug and pH at the absorption site, 
contributing for that also the pH of formulation. 
At this point, it should be stated that the pH of 
formulation must be selected attending to drug 
stability and if possible should be assured the 
greatest quantity of non-ionized drug species. 
However, the pH of formulation can induce nasal 
mucosa irritation and, hence, it should be similar 
to that found on human nasal mucosa (5.0-6.5) 
(26, 35, 120). Besides, the pH often prevents the 
bacteria growth (11). In order to evaluate the 
effect of pH solution on the integrity of nasal 
mucosa, Pujara et al. (128) dissolved drugs in 
phosphate buffer at different pH values in the 
range of 2-12. The study was performed in rats 
whose nasal pH is 7.39 (121) and the results 
demonstrated that when pH ranged from 3-10 
minimal quantities of proteins and enzymes were 
released from cells, demonstrating no cellular 
damages. On the contrary, if pH values were 
below 3 or above 10 damages were observed 
intracellularly and at membrane level. 
 
4.3.3. Pharmaceutical form 
 
Nasal drops are the simplest and the most 
convenient nasal pharmaceutical form, but the 
exact amount of drug delivered is not easily 
quantified and often results in overdose (6). 
Moreover, rapid nasal drainage can occur when 
using this dosage form. Solution and suspension 
sprays are preferred over powder sprays because 
the last one easily prompted the development of 
nasal mucosa irritation (104). Recently, gel-
devices have been developed for a more accurate 
drug delivery. They reduce postnasal drip and 
anterior leakage, fixing the drug formulation in 
nasal mucosa. This enhances the drug residence 
time and diminishes MCC, thereby, potentially 
increases the nasal absorption. Over the last years, 
specialized systems such as lipid emulsions, 
microspheres, liposomes and films have also been 
developed to improve nasal drug delivery.  
 
4.3.4. Pharmaceutical excipients 
 
In nasal formulations, a wide variety of 
pharmaceutical excipients can be found and they 
are selected accordingly to their functions. 
Solubilizers, buffer components, antioxidants, 
preservatives, humectants, gelling/viscosifying 
agents, and flavoring or taste masking agents are 
some of the most usual excipients (6). Although 
they are responsible for several nasal irritations, 
antioxidants, preservatives, humectants and 
flavoring or taste masking agents are not expected 
to alter nasal drug absorption (6). 
 
5. STRATEGIES TO INCREASE NASAL 
DRUG ABSORPTION  
 
Although the intranasal route is efficient for topic, 
systemic and CNS delivery of a wide range of 
drugs, it cannot be applied for many others due to 
their low nasal bioavailability. Briefly, 
bioavailability of nasally administered drugs is 
particularly restricted by low drug solubility, 
rapid enzymatic degradation in nasal cavity, poor 
membrane penetration and rapid MCC. 
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Figure 5. Factors affecting nasal drug absorption and practical strategies to overcome them. 
 
 
 
Several approaches have been suggested to 
overcome these limitations, including the use of 
prodrugs, enzymatic inhibitors, absorption 
enhancers, development of mucoadhesive 
delivery systems and new pharmaceutical forms 
(Figure 5 and Table 4). 
 
 
5.1. Prodrugs 
 
The term ‘prodrug’ was coined by Albert in 1951 
(129) and it is used to describe compounds that 
undergo biotransformation prior to exhibiting 
their pharmacological effect. Over the years, 
prodrugs have been used to overcome drugs’ bad 
taste, poor solubility, insufficient stability, 
Table 4. Common problems associated to low nasal bioavailability of drugs, challenges and possible 
solutions. 
Problem Challenge Solution 
Poor physicochemical 
properties of drug and/or 
formulation 
Improve physicochemical properties of drug 
and/or formulation  
 Prodrugs 
 Cosolvents 
 Cyclodextrins 
 Pharmaceutical excipients 
 Novel drug formulations 
Enzymatic degradation Reduce drug affinity to nasal enzymes  Prodrugs 
 Inhibit nasal enzymes  Enzymatic inhibitors 
 Protect drugs from nasal enzymes  Prodrugs 
 Cosolvents 
Low permeability through 
nasal membrane 
Increase drug permeability and dissolution  Prodrugs 
 Cosolvents 
 Modify nasal membrane  Absorption enhancers 
 Enhance drug residence time in nasal cavity  Mucoadhesive systems 
 Gelling/Viscosifying agents 
Physiological 
factors of nasal 
mucosa
Characteristics of 
the drug
Properties of the 
formulation
Nasal Drug
Absorption
Increase
Prodrugs
Enzymatic inhibitors
Absorption enhancers
Mucoadhesive drug delivery systems 
Novel formulation forms
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incomplete absorption across biological barriers 
and premature metabolism to inactive or toxic 
species (130). 
Intranasal drugs are commonly administered 
as solutions or as powder formulations which 
need to undergo a dissolution process before 
absorption. Lipophilic drugs easily pass through 
biomembranes, however they are poorly water-
soluble. In this way, they should be administered 
as a prodrug with higher hydrophilic character in 
order to make possible the production of an 
aqueous nasal formulation with a suitable 
concentration. Once in the blood stream, the 
prodrug must be quickly converted to the parent 
drug. For instance, L-Dopa is poorly soluble in 
water, so it is very difficult to develop a 
corresponding intranasal aqueous formulation 
with an effective dose. Kao et al. (101) produced 
various prodrugs of L-Dopa and observed that 
their solubility enhanced significantly in 
comparison with the parent drug (Figure 6), 
allowing, hence, the development of adequate 
nasal formulations. Furthermore, their nasal 
administration resulted in a rapid and complete 
absorption to the systemic circulation, where 
quick conversion to L-Dopa takes place. Similar 
results were obtained for testosterone which is 
also poorly water-soluble (127). 
In contrast, very hydrophilic polar drugs may 
not have ability to cross biomembranes. Thereby, 
if they are administered as prodrugs with higher 
lipophilic character, the penetration through the 
membrane may increase (131). Some researches 
have also used the prodrug approach for 
improving enzymatic stability of drugs. For 
example, Yang et al. (63) stated that L-aspartate-
β-ester prodrug of acyclovir was more permeable 
and less labile to enzymatic hydrolysis than its 
parent drug. In addition, the potential use of 
prodrugs to protect peptide drugs from nasal 
enzymatic degradation has been discussed and 
suggested as a powerful strategy to increase the 
bioavailability of peptides when intranasally 
administered (11, 13, 100).  
An alternative approach to the use of prodrugs 
in order to increase drug solubility is the use of 
co-solvents (13). Co-solvents most used in 
intranasal formulations include glycerol, ethanol, 
propyleneglycol and polyethylene glycol and may 
be of the most importance since they are non-
toxic, pharmaceutically acceptable and non-
irritant to nasal mucosa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. L-Dopa and its water soluble prodrugs (101). 
 
 
5.2. Enzymatic inhibitors 
 
Nasal mucus layer and nasal mucosa act as 
enzymatic barriers during nasal drug delivery, 
because they have a wide variety of enzymes. 
Various approaches have been used to avoid 
enzymatic degradation, including the use of 
proteases and peptidases inhibitors. For example, 
bestatine and comostate amylase are used as 
aminoptidases inhibitors and leupeptine and 
aprotinin as trypsine inhibitors probably involved 
in the degradation of calcitonin (125). 
Furthermore, bacitracin, amastatin, boroleucin 
and puromycin (124-126) have been used to avoid 
enzymatic degradation of drugs such as leucine 
enkephalin (132, 133) and human growth 
hormone (134). Finally, enzymatic inhibition can 
also be achieved using certain absorption 
Increase water solubility 
L-Dopa Methyl ester Benzyl ester Cyclohexyl ester Pentyl ester Butyl ester 
L-Dopa prodrugs 
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enhancers (bile salts and fusidic acid) (13). It is 
demonstrated that disodium ethylene-
diaminetetraacetate, an absorption enhancer, 
reduces enzymatic degradation of beta sheet 
breaker peptide used for the treatment of 
Alzheimer’s disease (135). 
 
5.3. Absorption enhancers 
 
Small and large hydrophilic drugs may be poorly 
permeable across nasal epithelium and may show 
an insufficient bioavailability. It is possible to 
greatly improve their absorption if they are 
administered in combination with absorption 
enhancers which induce reversible modifications 
on the structure of epithelial barrier. In intranasal 
drug delivery, absorption enhancers most used are 
surfactants (laureth-9), bile salts, fatty acids 
(taurodihydrofusidate) and polymeric enhancers 
(chitosan, cyclodextrins, poly-L-arginine and 
aminated gelatine) (37, 57, 105, 136-140). 
The mechanism of action of absorption 
enhancers is not well known but, generally, they 
change the permeability of epithelial cell layer by 
modifying the phospholipidic bilayer, increasing 
membrane fluidity or opening tight junctions 
between epithelial cells and, thus, increasing 
paracellular transport (58). Although the 
absorption promoters enhance drug 
bioavailability, a direct relation between this 
effect and the damage caused in the membrane 
may sometimes exist (141, 142). In fact, 
surfactants, bile salts, fatty acids, phospholipids 
and lyso-phospholipids modify cell structures, 
leaching out proteins or even stripping off the 
outer layer of the mucosa (4, 7). On the other 
hand, some promoters such as chitosan, 
cyclodextrins and selected phospholipids present 
an absorption enhancing effect that greatly 
outweighs any modification caused in mucosa. 
Indeed, they act mainly by opening the tight 
junctions. Moreover, polymeric enhancers present 
high molecular weight and, hence, they are not 
absorbed, minimizing systemic toxicity in 
comparison with enhancers of low molecular 
weight.  
A wide range of absorption enhancers are 
evaluated in animal models. Special caution is 
required when interpreting these results as they 
can be grossly overestimated when compared 
with human studies. Probably, this results from 
distinct architectures and morphologies of nasal 
cavity in different species (4, 7) as resumed in 
Table 5. Thus, during the choice of an absorption 
enhancer to include in an intranasal formulation, 
it is essential to assure a good absorption 
enhancing and minimal toxic effects. Considering 
the wide variety of absorption enhancers that may 
be used in intranasal administration, this review 
will only discuss those ones which are more used 
as a result of their significant enhancing effect 
and their low toxicity. 
 
5.3.1. Chitosan 
 
Chitosan is a linear polysaccharide biopolymer 
produced by deacetylation of chitin, the main 
component of crustacean’s exoskeleton (13). Due 
to its biodegradability, biocompatibility and 
bioadhesive properties associated to a low 
toxicity, chitosan is widely used in intranasal 
formulations. It is believed that it interacts with 
protein kinase C system and opens the tight 
junctions between epithelial cells (98), increasing 
paracellular transport of polar drugs. Moreover, it 
interacts strongly with nasal mucus layer 
enhancing the contact time for the transport of the 
drug across the membrane (4, 143-145). Finally, 
chitosan also enhances the dissolution rate of low 
water soluble drugs (120, 128). Consequently, 
chitosan is used in several intranasal 
pharmaceutical forms, including powders, liquids, 
gels, microparticles and microspheres. For some 
drugs, it is well documented that the addition of 
chitosan to nasal formulation increases drug 
bioavailability. Some of the most studied drugs 
are insulin (7, 55) and morphine (4, 7, 51). 
 
5.3.2. Cyclodextrins 
 
Cyclodextrins are cyclic oligossacharides 
composed of glucose units joined trough α-1,4-
glycosidic bonds resulted from bacterial digestion 
of cellulose. Structurally, they have a hydrophilic 
outer surface and a lipophilic central cavity where 
apolar drugs can be included (146, 147). 
Cyclodextrins are used as complexing agents to 
improve nasal drug absorption by increasing drug 
solubility and stability. They can also work as 
absorption enhancers, since they interact with the 
lipophilic components of biological membranes 
changing their permeability (13, 35, 148-150). 
Although widely used in intranasal medicinal 
preparations, cyclodextrins present some local 
and systemic toxicity. Moreover, alterations of 
nasal morphology, ciliary beat frequency, 
erythrocyte haemolysis and citotoxic effects have 
also been reported (151). 
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Table 5. Characteristics of nasal cavity of different animal species (26, 97). 
Nasal Cavity Species 
 Human Rat Rabbit Monkey Dog 
Length (cm) 7.5 2.3 5.2 5.3 10.0 
Volume (cm3) 20.0 0.4 6.0 8.0 20.0 
Surface area (cm2) 150.0 14.0 61.0 61.6 220.7 
Olfactory area (cm2) 10.0 7.0 6.0 NF NF 
NF, not found. 
 
 
5.3.3. Mucoadhesive drug delivery systems 
 
MCC is one of the most important limiting factors 
for nasal drug delivery, because it reduces the 
time allowed for drug absorption. Thus, 
improving nasal drug absorption can also be 
achieved prolonging the contact time between 
drug and nasal mucosa. In this way, 
mucoadhesive drug delivery systems have been 
developed (65, 89, 152-154). Mucoadhesion 
implies the attachment of the drug delivery 
system to the mucus, involving an interaction 
between mucin and a synthetic or natural polymer 
called mucoadhesive. The sequential events that 
occur during this mucoadhesion include several 
steps. Firstly mucoadhesive systems absorb water 
from mucus layer and get wet and swelling. 
Following this, the polymer intimately penetrates 
into the mucus (155) and, hence, localizes the 
formulation in nasal cavity, enhancing the drug 
concentration gradient across the epithelium. 
Mucoadhesives mostly used in intranasal drug 
delivery are chitosan, alginate and cellulose or its 
derivatives. Some of them may present other 
important characteristics which also enhance drug 
absorption. For example, chitosan is 
mucoadhesive and also causes a transient 
widening of epithelial tight junctions. Carbacol 
934P and polycarbophil are mucoadhesive 
polymers that inhibit the trypsin proteolytic 
enzyme and, therefore, they can be used also to 
increase the stability of peptide drugs (155). 
Sodium alginate is a water-soluble, natural, linear 
polysaccharide which is widely used as a polymer 
matrix due to its non-toxicity, biocompatibility 
and gel formation stability. Indeed, it has the 
highest mucoadhesive strength compared with 
polymers such as polystyrene, chitosan, 
carboxymethylcellulose and poly(lactic acid) 
(155). 
 
 
 
5.4. Novel drug formulations 
 
Several claims have been made in favour of 
developing nasal formulations containing 
liposomes, microspheres and nanoparticles for 
intranasal drug delivery. These systems can 
include, besides the drug, enzymatic inhibitors, 
nasal absorption enhancers or/and mucoadhesive 
polymers in order to improve the stability, 
membrane penetration and retention time in nasal 
cavity. In fact, it is not clear if those formulations 
increase drug absorption by transporting 
encapsulated drug across the membrane or just 
because they enhance the nasal retention time and 
stability of the drug. However, their use is in 
widespread growth and the results have been very 
promising. 
 
5.4.1. Liposomes 
 
Liposomes are phospholipids vesicles composed 
by lipid bilayers enclosing one or more aqueous 
compartments and wherein drugs and other 
substances can be included. Liposomal drug 
delivery systems present various advantages such 
as the effective encapsulation of small and large 
molecules with a wide range of hydrophilicity and 
pKa values (64). In fact, they have been found to 
enhance nasal absorption of peptides such as 
insulin and calcitonin by increasing their 
membrane penetration (156, 157). This has been 
attributed to the increasing nasal retention of 
peptides (157), protection of the entrapped 
peptides from enzymatic degradation (158, 159) 
and mucosal membrane disruption (160). Jain et 
al. (156) incorporated insulin in liposomes coated 
with chitosan and carbapol and administered them 
intranasally to rats. The results demonstrated that 
this formulation was effective and that its 
mucoadhesive property is a viable option for a 
sustained release of insulin. The same work has 
demonstrated the usefulness of novel 
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mucoadhesive multivesicular liposomes for 
transmucosal insulin delivery. 
Moreover, liposomal drug delivery systems 
were also reported as useful for influenza vaccine 
(65) and non-peptide drugs such as nifedipine 
(161). Liposomes can be incorporated in different 
formulations. For example, Ding et al. (48) 
obtained a rapid onset of action and sustained 
delivery of levonorgestrel when it was 
intranasally administered as a liposome 
suspension. Furthermore, positive results were 
also found during nasal delivery of acyclovir in a 
liposomal gel (64). The use of a liposomal gel not 
only promoted the prolonged contact between the 
drug and the absorptive site, but also facilitated 
direct absorption through the nasal mucosa. These 
conclusions were obtained comparing liposomal 
formulations and free drug suspended in gel. 
 
5.4.2. Microspheres 
 
Microsphere technology has been widely applied 
in designing formulations for nasal drug delivery 
(57, 152-154, 162). Microspheres are usually 
based on mucoadhesive polymers (chitosan, 
alginate), which present advantages for intranasal 
drug delivery. Furthermore, microspheres may 
also protect the drug from enzymatic metabolism 
and sustain drug release, prolonging its effect 
(153, 162). Wang et al. (57) have investigated 
aminated gelatin microspheres as a nasal drug 
delivery system for insulin. They have observed a 
significant hypoglycemic effect when 
administered intranasally in dry powder form to 
rats, but no significant effect was achieved when 
given in a suspension. Gavine et al. (152) have 
analyzed nasal mucosa after its exposure to 
microspheres of alginate/chitosan containing 
metoclopramide. They observed open tight 
junctions in the epithelium and also stated that 
these spray-dried microspheres have promising 
properties as mucoadhesive nasal carriers. Many 
other similar studies have been carried out and 
positive results are found for nasal delivery of 
carbamazepine using chitosan microspheres 
(162), cyclodextrins using chitosan and alginate 
as mucoadhesive polymers (153) and carvedilol 
using alginate mucoadhesive microspheres (154). 
 
5.4.3. Nanoparticles 
 
Recently, much attention has been given to 
nanotechnology in many areas. Nanoparticle 
systems are being investigated to improve drug 
delivery and intranasal drug administration. 
Nanoparticles are solid colloidal particles with 
diameters raging from 1-1000 nm (163). They 
consist of macromolecular materials and can be 
therapeutically used as adjuvant in vaccines or as 
drug carriers, in which the active substance is 
dissolved, entrapped, encapsulated, adsorbed or 
chemically attached (163). Nanoparticles may 
offer several advantages due to their small size, 
but only the smallest nanoparticles penetrate the 
mucosal membrane by paracellular route and in a 
limited quantity because the tight junctions are in 
the order of 3.9-8.4 Å (98). 
Controversial results are found when using 
nanoparticles in intranasal drug delivery (98, 164-
168). In fact, there are few publications wherein 
nanoparticle formulations don’t significantly 
enhance the drug transport across the nasal cavity 
(98). The low bioavailability obtained can be due 
to the fact that particles are probably taken up by 
M-cells in the nasal associated lymphoid tissue 
and, therefore, transported into the lymphatic 
system and blood stream (35, 98). In contrast, 
other studies have suggested that nanoparticle 
systems may be ideally suited for the delivery of 
nasal vaccines (76, 169-171). 
 
6. CONCLUSION 
 
Considering the widespread interest in nasal drug 
delivery and the potential benefits of intranasal 
administration, it is expected that novel nasal 
products will continue to reach the market. They 
will include not only drugs for acute and long-
term diseases, but also novel nasal vaccines with 
better local or systemic protection against 
infections. The development of drugs for directly 
target the brain in order to attain a good 
therapeutic effect in CNS with reduced systemic 
side effects is feasible. 
However, it was also stated that intranasal 
route presents several limitations which must be 
overcome to develop a successful nasal medicine. 
Physiological conditions, physicochemical 
properties of drugs and formulations are the most 
important factors determining nasal drug 
absorption. The use of prodrugs, enzymatic 
inhibitors, absorption enhancers, mucoadhesive 
drug delivery systems and new pharmaceutical 
formulations are, nowadays, among the mostly 
applied strategies. Each drug is one particular 
case and, thus, the relationship between the drug 
characteristics, the strategies considered and the 
permeation rate is essential. 
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The era of nasal drug delivery is growing. 
However, new efforts are needed to make this 
route of delivery more efficient and popular. 
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